NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Sudo Biosciences

Sudo Biosciences

Private
Carmel, IndianaHealthcare & Life Scienceshttps://sudobio.com/

Last Round

Series B

Feb 13, 2024

Total Funding Raised

$218M

Company Overview

Sudo Biosciences is a biopharmaceutical company that develops innovative medicines targeting the TYK2 pseudokinase domain to treat immune-mediated inflammatory conditions, including multiple sclerosis and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

TYK2 inhibitorbrain-penetrant drugneuroinflammatory diseaseautoimmune treatmentblood-brain barrierclinical-stage biotechsmall-molecule drugCNS drugdrug pipelinebiotech startupallosteric inhibitorpharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sudo Biosciences Comps

Public and private peers based on sector, stage, and business model.

Sudo Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Sudo Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 13, 2024
Series BDec 20, 2023
Series ASep 28, 2022
SeedDec 31, 2020

Key People

Founding team and executive leadership

Scott Byrd

Chief Executive Officer

Executive Team

Sudo Biosciences Investors

Notable investors and investment history

Sudo Biosciences investors
InvestorRounds
Enavate SciencesSeries B
Surveyor CapitalSeries B
Frazier Healthcare PartnersSeries A
SV Health InvestorsSeries B
Northern TrustSeries B
Eventide FundsSeries B
Monograph CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 4, 2025

    Paul S. Bavier appointed as Chief Legal Officer.

  • Feb 13, 2024

    $30M round completed.

Sudo Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sudo Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sudo Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersCarmel, Indiana
Employee Range27
Year Founded2020
Last FundingFeb 13, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.